Editorial: Future frontiers in the management of metastatic colorectal cancer
Francesco Giovinazzo,Gaetano Gallo,Marta Goglia,Matteo Pavone,Alessandro Coppola,Emanuela Dell'Aquila
DOI: https://doi.org/10.3389/fonc.2024.1486653
IF: 4.7
2024-10-04
Frontiers in Oncology
Abstract:Metastatic colorectal cancer (mCRC) remains a tough challenge in oncology, with a survival rate of just 14% over five years, underscoring the need for innovative and effective treatments. Despite advances in surgery, chemotherapy, and targeted therapies, mCRC often remains incurable, highlighting the critical need for continued research and development in treatment modalities. In recent years, significant progress has been made in mCRC treatment, and the introduction of novel chemotherapeutic and targeted therapy agents has been marked. For instance, the combination of Trifluridine and Tipiracil with bevacizumab has emerged as a promising option for patients who have exhausted standard treatments. This combination has shown efficacy in prolonging survival and improving quality of life, marking a significant milestone in managing mCRC. Indeed, in their study, Rais et al., analysed published clinical trials on their combination, reporting that available evidence in oncology have shown that combining bevacizumab with trifluridine/tipiracil significantly improves outcomes in heavily pre-treated metastatic mCRC patients. This combination therapy enhances progression-free survival (PFS) and overall survival (OS) compared to trifluridine/tipiracil alone, though it is associated with higher rates of severe neutropenia. Moreover, multiple studies, including the SUNLIGHT phase 3 trial, confirm these benefits, particularly in patients with RAS-mutated tumours. In fact, despite some limitations in study design, the combination demonstrates a good safety profile and promising efficacy.Numerous attempts are constantly made every day to increase knowledge of the biological mechanisms underlying the pathogenesis of this tumour disease with the clear aim of preventing it. To this end, the group of Wang et al. studied the incidence of liver metastases after colorectal cancer in the general population and in the elderly population by analysing a huge national database (numbering 32,330 patients) in order to identify some independent predictive factors and prognostic factors. In their analysis they found that there are 13 factors that have an impact on the incidence of liver metastases in the general population and these are age at diagnosis, marital status, race, bone metastases, lung metastases, CEA level, tumour size, grade, histology, primary site, T stage, N stage and sex. Whereas in the elderly population 10 variables, including age at diagnosis, CEA level, tumour size, lung metastases, bone metastases, chemotherapy, surgery, N stage, grade, and race, have been shown to be independent prognostic predictors.In addition Song et al. discussed in their paper the growing importance of accurately predicting lymph node metastasis in T1 colorectal cancer due to increasing early detection rates. Indeed, they review already known and emerging predictors, including pathological factors, clinical tests, molecular biomarkers, and AI-based risk models, to determine the need for additional surgery after endoscopic resection. They highlighted that current predictive scoring systems for lymph node metastasis (LNM) in early CRC are mainly based on pathological parameters, but their accuracy is still limited. Some of the recent studies analysed in their review suggest incorporating new predictors like width of submucosal invasion (WSI), area of submucosal invasion (ASI), and clinical test factors such as fibrinogen, which show greater predictive power. Molecular biomarkers and AI-based models also hold promise for improving LNM prediction accuracy. This might represent a great advance in the management of early CRC patients.Surgical intervention is crucial in managing colorectal cancer, especially when addressing liver metastases. The introduction of minimally invasive surgical techniques, such as laparoscopic and robotic-assisted liver resections, has significantly advanced the field. These techniques minimize the physical trauma of surgery, leading to shorter recovery times, reduced pain, and fewer complications compared to traditional open surgeries. They maintain oncological efficacy, ensuring that cancerous tissues are effectively removed while promoting faster patient recovery and return to normal activities. Additionally, these approaches often result in better cosmetic outcomes and fewer postoperative restrictions, enhancing overall patient satisfaction. As technology and surgical expertise continue to evolve, these minimally invasive procedures will likely become the standard for treating colorectal cancer with liver involvement, providing patients with safer and more effective options (1).With the purpose of comparing MIS and open technique, which represented the standard of care for many years and which is still broadly diffused, the group of Pinto et al., conducted a systematic review on the two different surgical approach for surgical resection of liver metastasis in colorectal -Abstract Truncated-
oncology